ABC-3TC + LPV-RTV versus TDF-FTC + LPV-RTV
HEAT Trial
ABC-3TC + LPV-RTV versus TDF-FTC + LPV-RTV in Treatment Naïve
HEAT: Study Design

Study Design: HEAT

• **Background**: Randomized, double-blind, placebo-matched phase IV study comparing the efficacy, safety, and tolerability of abacavir-lamivudine versus tenofovir DF-emtricitabine in combination with lopinavir-ritonavir in treatment-naïve patients with HIV infection.

• **Inclusion Criteria** (n = 688)
  - Age ≥18
  - Antiretroviral-naïve
  - HIV RNA ≥1000 copies/mL
  - No CD4 criteria, no HLA-B*5701 screening done

• **Treatment Arms**
  - Abacavir-lamivudine + lopinavir-ritonavir BID
  - Tenofovir DF-emtricitabine + lopinavir-ritonavir BID

**HEAT** = HIV study with Epizicom And Truvada

ABC-3TC + LPV-RTV versus TDF-FTC + LPV-RTV in Treatment Naïve
HEAT: Results

Week 48: Virologic Response (ITT, Missing=Failure)

ABC-3TC + LPV-RTV versus TDF-FTC + LPV-RTV in Treatment Naïve
HEAT: Results

Week 96: Virologic Response (ITT, Missing=Failure)

ABC-3TC + LPV-RTV versus TDF-FTC + LPV-RTV in Treatment Naïve HEAT: Results

<table>
<thead>
<tr>
<th>Adverse Event</th>
<th>ABC-3TC + LPV/r (n = 343)</th>
<th>TDF-FTC + LPV/r (n = 345)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Any drug-related grade 2-3 AEs</td>
<td>50%</td>
<td>46%</td>
</tr>
<tr>
<td>Any drug-related grade 3-4 AEs</td>
<td>15%</td>
<td>15%</td>
</tr>
<tr>
<td>Serious drug-related AEs</td>
<td>5%</td>
<td>3%</td>
</tr>
</tbody>
</table>

**Conclusion:** “Both ABC/3TC and TDF/FTC provided comparable antiviral efficacy, safety, and tolerability when each was combined with lopinavir/ritonavir in treatment-naive patients.”
Acknowledgment

The **National HIV Curriculum** is an AIDS Education and Training Center (AETC) Program resource funded by the United States Health Resources and Services Administration. The project is led by the University of Washington and the AETC National Coordinating Resource Center.

*The content in this slide set does not represent the official views of the U.S. Department of Health and Human Services, Health Resources & Services Administration.*